PPT-Applying Science to Improve the Individualized Treatment of Patients with Psoriasis

Abrar Qureshi MD MPH Chief of the Department of Dermatology Rhode Island Hospital Chair Department of Dermatology The Warren Alpert Medical School of Brown University Patient Case Studies History and Clinical Presentation. Press Conference. 28 October 2014. Welcome. Prof. . Myrto. . Trakatelli. Dermatologist. Miss . Dufourny. Dominique . Alderwomen of Ixelles. Prof Erwin . Tschachler. . Presentation of the Campaign. in . a . Primary . Care Setting. Gain the . upper hand . on psoriasis. AbbVie Disclosure. This Program is sponsored by, and on behalf of, AbbVie, and the presentation contents are consistent with all applicable FDA guidelines. The Speaker for this program has been selected by . IL-17 Inhibitors in the Management of Psoriatic Disease . Agenda. Treat-to-Target in PsA. Early Intervention and Tight Control of Inflammation in Patients With PsA: TICOPA . MDA Criteria. TICOPA: Commonly Reported AEs. Psoriasis is a chronic, autoimmune skin disease that speeds up the growth cycle of skin cells.. Psoriasis . is commonly mistaken as "just a skin condition." But it's actually a chronic (long-lasting) disease of the immune system. Rheumatology Nurse Practitioner. University of Washington School of Nursing. Affiliate Assistant Professor. Seattle, WA. Dr. Dewing has no conflicts of interest to disclose.. Please complete the . pre-activity survey.. Click on icon. or. . From the View menu, select the Slide Show option. * . To help you as you prepare a talk, we have included the relevant text from ITC in the notes pages of each slide . Psoriasis. Eczema. Polymorphic Light Eruption (PLE). Vitiligo. Prurigo. . Pruritis. Skin conditions that can be treated with phototherapy. Affects 2-4% of the population. Male and female equally. Peaks around age of 15-25 and 50-60 but can occur at any age. . Hasan. M.B.CH.B. C.A.B.S-D.V. Psoriasis is a chronic, non-infectious, inflammatory skin disorder, characterized by well-defined . salmonpink. . plaques bearing large adherent silvery centrally attached scales.. Abid. . Psoriasis Description. Inflammatory, common, chronic, . genodermatosis. which appears to be due abnormal t lymphocytes function. may be affected Skin, nails and joints forms.. There are several distinct clinical type .  Address for correspondence: Prof. Adam Reich MD, PhD, Department of Dermatology, University of Rzeszow, 2 Szopena St, 35-055 Rzeszow, Poland, phone: +48076 722, e-mail: adi_medicalis@g Tamara Arabiyat. Psoriasis is a chronic inflammatory systemic autoimmune disease.. Globally, 1-2% of the population is affected by psoriasis.. Prevalence is equal in males and females.. In monozygotic twins, if one twin has the disease, the other one has a 70% chance of being affected. In dizygotic twins, there is only a 20% chance. . Psoriasis is a noncontagious skin disorder that most commonly appears as inflamed, edematous skin lesions covered with a silvery white scale. The most common type of psoriasis is plaque psoriasis . Causes . Reich K, et al.. Methods. Patients with moderate-to-severe plaque psoriasis were randomized 1:1 to:. Bimekizumab 320 mg every 4 weeks. S. ecukinumab 300 mg every 4 weeks after the usual weekly secukinumab loading dose for the first 5 doses. Andrew Blauvelt and Colleagues. 2022 AAD Annual Meeting. https://eposters.aad.org/abstracts/33884. Skin Clearance and Quality of Life. Multiple drugs have good data for skin clearance. Skin clearance has not been directly correlated with quality of life.